Home Tools
Log in
Cart

Epigenetic Reader Domain

Epigenetic reader domains can be thought of as effector proteins that recognize and are recruited to specific epigenetic marks.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T17249 VZ185 2306193-61-1 98%
VZ185
VZ185 is an effective and selective dual BRD7/9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).
T11292 FKBP12 PROTAC dTAG-7 2064175-32-0 98%
FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin l...
T77680 BRD7-IN-3 98%
BRD7-IN-3
BRD7-IN-3 (compound 1-78) functions as a dual inhibitor targeting the bromodomain-containing proteins BRD7 and BRD9, demonstrating half-maximal inhibitory concen...
T77975 PROTAC BRD9 Degrader-6 2676211-62-2 98%
PROTAC BRD9 Degrader-6
PROTAC BRD9 Degrader-6, with an IC50 value of 0.13 nM, is a potent degrader of BRD9 suitable for research on BAF complex-related disorders [1].
T78142 DC-BPi-11 hydrochloride 98%
DC-BPi-11 hydrochloride
DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferat...
T78151 Bleximenib oxalate 2866179-95-3 98%
Bleximenib oxalate
Menin-MLL Inhibitor 24 (compound A) oxalate, a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, is utilized in cancer research [1].
T78202 IV-255 98%
IV-255
IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain, heightening DNA damage when administered with Temozolomide and Bleomycin. It also curtail...
T15419 GS-626510 1637770-13-8 98%
GS-626510
GS-626510 is an orally bioavailable inhibitor of BET family bromodomains (Kd: 0.59-3.2 nM for BRD2/3/4; IC50: 83 nM and 78 nM for BD1 and BD2).
T78660 (S,R)-CFT8634 2704617-95-6 98%
(S,R)-CFT8634
(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferat...
T78682 SJ1461 2924546-70-1 98%
SJ1461
SJ1461 is a potent, orally active inhibitor of the BET family, selectively targeting and inhibiting BRD2 (BD1), BRD2 (BD2), BRD4 (BD1), and BRD4 (BD2) with respe...
T78801 BRD7-IN-2 98%
BRD7-IN-2
BRD7-IN-2 (compound 2-77) is a potent selective inhibitor of bromodomain-containing protein 7 (BRD7), exhibiting significant anti-proliferative activity in prost...
T78851 BRD4 Inhibitor-28 2468960-80-5 98%
BRD4 Inhibitor-28
BRD4 Inhibitor-28 (Compound 18), an orally active molecule, selectively inhibits the bromodomains of BRD4 (BRD4-BD1 and BRD4-BD2) with IC50 values of 15 and 55 n...
T78923 DDO-8926 98%
DDO-8926
DDO-8926 is a potent, selective BET inhibitor shown to markedly diminish mechanical hypersensitivity in neuropathic pain research by suppressing pro-inflammatory...
T78933 BD-9136 98%
BD-9136
BD-9136, a highly selective BRD4 degrader, demonstrates the capability to inhibit tumor growth without inducing adverse effects in mice, showing potential for ca...
T78956 PROTAC BRD3/BRD4-L degrader-2 98%
PROTAC BRD3/BRD4-L degrader-2
PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits r...
T78989 BET-IN-16 2089390-09-8 98%
BET-IN-16
BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells. It exhibi...
T79016 BET-IN-14 2243669-93-2 98%
BET-IN-14
BET-IN-14 is a pan BET inhibitor with an IC50 of 5.35 nM, demonstrating oral activity and anticancer properties [1].
T79017 GSK737 2748687-95-6 98%
GSK737
GSK737 is a dual inhibitor of BRD4 BD1 and BD2, exhibiting pIC50 values of 5.3 and 7.3, respectively. It demonstrates low clearance, along with favorable solubil...
T79018 GSK217 2748687-92-3 98%
GSK217
GSK217 is a potent and selective inhibitor of the bromo and extraterminal domain (BET) second bromodomain (BD2) with high solubility, utilized in oncology and im...
T79034 GXF-111 98%
GXF-111
GXF-111, a proteolysis targeting chimera (PROTAC) molecule, efficiently induces the selective degradation of the BRD3 and BRD4-L proteins. It exhibits high bindi...
VZ185
T17249
VZ185 is an effective and selective dual BRD7/9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).
FKBP12 PROTAC dTAG-7
T11292
FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin l...
BRD7-IN-3
T77680
BRD7-IN-3 (compound 1-78) functions as a dual inhibitor targeting the bromodomain-containing proteins BRD7 and BRD9, demonstrating half-maximal inhibitory concen...
PROTAC BRD9 Degrader-6
T77975
PROTAC BRD9 Degrader-6, with an IC50 value of 0.13 nM, is a potent degrader of BRD9 suitable for research on BAF complex-related disorders [1].
DC-BPi-11 hydrochloride
T78142
DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferat...
Bleximenib oxalate
T78151
Menin-MLL Inhibitor 24 (compound A) oxalate, a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, is utilized in cancer research [1].
IV-255
T78202
IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain, heightening DNA damage when administered with Temozolomide and Bleomycin. It also curtail...
GS-626510
T15419
GS-626510 is an orally bioavailable inhibitor of BET family bromodomains (Kd: 0.59-3.2 nM for BRD2/3/4; IC50: 83 nM and 78 nM for BD1 and BD2).
(S,R)-CFT8634
T78660
(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferat...
SJ1461
T78682
SJ1461 is a potent, orally active inhibitor of the BET family, selectively targeting and inhibiting BRD2 (BD1), BRD2 (BD2), BRD4 (BD1), and BRD4 (BD2) with respe...
BRD7-IN-2
T78801
BRD7-IN-2 (compound 2-77) is a potent selective inhibitor of bromodomain-containing protein 7 (BRD7), exhibiting significant anti-proliferative activity in prost...
BRD4 Inhibitor-28
T78851
BRD4 Inhibitor-28 (Compound 18), an orally active molecule, selectively inhibits the bromodomains of BRD4 (BRD4-BD1 and BRD4-BD2) with IC50 values of 15 and 55 n...
DDO-8926
T78923
DDO-8926 is a potent, selective BET inhibitor shown to markedly diminish mechanical hypersensitivity in neuropathic pain research by suppressing pro-inflammatory...
BD-9136
T78933
BD-9136, a highly selective BRD4 degrader, demonstrates the capability to inhibit tumor growth without inducing adverse effects in mice, showing potential for ca...
PROTAC BRD3/BRD4-L degrader-2
T78956
PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits r...
BET-IN-16
T78989
BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells. It exhibi...
BET-IN-14
T79016
BET-IN-14 is a pan BET inhibitor with an IC50 of 5.35 nM, demonstrating oral activity and anticancer properties [1].
GSK737
T79017
GSK737 is a dual inhibitor of BRD4 BD1 and BD2, exhibiting pIC50 values of 5.3 and 7.3, respectively. It demonstrates low clearance, along with favorable solubil...
GSK217
T79018
GSK217 is a potent and selective inhibitor of the bromo and extraterminal domain (BET) second bromodomain (BD2) with high solubility, utilized in oncology and im...
GXF-111
T79034
GXF-111, a proteolysis targeting chimera (PROTAC) molecule, efficiently induces the selective degradation of the BRD3 and BRD4-L proteins. It exhibits high bindi...
1 2 3 4 5 6 7 8 9 10 11 12 13 14
TargetMol